Kura Oncology Quote - KURA

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

9.1738

Bid

8.69

Ask

9.90

Volume

3,204,000

8.88 Day's Range 9.17

8.85 52 Week Range 24.17

Market Cap

713.389M

Previous Close

8.97

Open

8.92

Last Trade

9.1

Last Trade Time

Financial Volume

US$ 28,836,336

VWAP

9.0001

Average Volume (3m)

1,527,319

Shares Outstanding

77,763,750

Dividend Yield

PE Ratio

-4.59

Earnings Per Share (EPS)

-1.96

Revenue

Net Profit

-152.63M

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Show more

Sector

Pharmaceutical Preparations

Industry

Blank Checks

Website

www.kuraoncology.com

Headquarters

Wilmington, Delaware, USA

Founded

2015

Kura Oncology Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KURA. The last closing price for Kura Oncology was US$8.97. Over the last year, Kura Oncology shares have traded in a share price range of US$ 8.85 to US$ 24.17.

Kura Oncology currently has 77,763,750 shares outstanding. The market capitalization of Kura Oncology is US$697.54 million. Kura Oncology has a price to earnings ratio (PE ratio) of -4.59.

Form 8-K - Current report

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients...

Kura Oncology to Host Virtual Investor Event on December 9, 2024

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...

Form 8-K - Current report

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias PR Newswire SAN DIEGO and TOKYO, Nov. 20, 2024 – Kura to receive a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.4362	-4.53902185224	9.61	10.02	8.85	2431123	9.28223389	CS
4	-0.8559	-8.53365504452	10.0297	11.62	8.85	2438342	10.39766688	CS
12	-10.5162	-53.4088369731	19.69	19.935	8.85	1527319	12.45347736	CS
26	-10.4562	-53.2664289353	19.63	23.48	8.85	1053233	15.0646782	CS
52	-3.9762	-30.2372623574	13.15	24.17	8.85	1064439	17.35892301	CS
156	-4.6962	-33.8586878154	13.87	24.17	7.41	901928	14.69738016	CS
260	-5.0362	-35.4412385644	14.21	43	6.34	798032	17.48836219	CS

KURA - Frequently Asked Questions (FAQ)

What is the current Kura Oncology share price?

The current share price of Kura Oncology is US$ 9.1738

How many Kura Oncology shares are in issue?

Kura Oncology has 77,763,750 shares in issue

What is the market cap of Kura Oncology?

The market capitalisation of Kura Oncology is USD 697.54M

What is the 1 year trading range for Kura Oncology share price?

Kura Oncology has traded in the range of US$ 8.85 to US$ 24.17 during the past year

What is the PE ratio of Kura Oncology?

The price to earnings ratio of Kura Oncology is -4.59

What is the reporting currency for Kura Oncology?

Kura Oncology reports financial results in USD

What is the latest annual profit for Kura Oncology?

The latest annual profit of Kura Oncology is USD -152.63M

What is the registered address of Kura Oncology?

The registered address for Kura Oncology is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Kura Oncology website address?

The website address for Kura Oncology is www.kuraoncology.com

Which industry sector does Kura Oncology operate in?

Kura Oncology operates in the BLANK CHECKS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MYSZMy Size Inc	US$ 4.2001 (211.12%)	120.01M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	76.64M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	33.95M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.61k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	120.4M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M